Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2000 May;76(895):280–286. doi: 10.1136/pmj.76.895.280

Alcoholic liver disease

K Walsh 1, G Alexander 1
PMCID: PMC1741594  PMID: 10775280

Abstract

Alcohol is a major cause of liver cirrhosis in the Western world and accounts for the majority of cases of liver cirrhosis seen in district general hospitals in the UK. The three most widely recognised forms of alcoholic liver disease are alcoholic fatty liver (steatosis), acute alcoholic hepatitis, and alcoholic cirrhosis. The exact pathogenesis of alcoholic liver injury is still not clear but immune mediated and free radical hepatic injury are thought to be important. There is increasing interest in genetic factors predisposing to hepatic injury in susceptible individuals. Diagnosis is based on accurate history, raised serum markers such as γ-glutamyltransferase, mean corpuscular volume, and IgA and liver histology when obtainable. Abstinence is the most important aspect of treatment. Newer drugs such as acamprosate and naltrexone are used to reduce alcohol craving. Vitamin supplements and nutrition are vital while corticosteroids have a role in acute alcoholic hepatitis where there is no evidence of gastrointestinal haemorrhage or sepsis. Liver transplantation has excellent results in abstinent patients with end stage liver disease but there are concerns about recidivism after transplant.


Keywords: cirrhosis; liver disease; alcohol

Full Text

The Full Text of this article is available as a PDF (133.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Becker U., Deis A., Sørensen T. I., Grønbaek M., Borch-Johnsen K., Müller C. F., Schnohr P., Jensen G. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996 May;23(5):1025–1029. doi: 10.1002/hep.510230513. [DOI] [PubMed] [Google Scholar]
  2. Bellentani S., Saccoccio G., Costa G., Tiribelli C., Manenti F., Sodde M., Saveria Crocè L., Sasso F., Pozzato G., Cristianini G. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut. 1997 Dec;41(6):845–850. doi: 10.1136/gut.41.6.845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Carmichael F. J., Orrego H., Saldivia V., Israel Y. Effect of propylthiouracil on the ethanol-induced increase in liver oxygen consumption in awake rats. Hepatology. 1993 Aug;18(2):415–421. [PubMed] [Google Scholar]
  4. Chataway J., Hardman E. Thiamine in Wernicke's syndrome--how much and how long? Postgrad Med J. 1995 Apr;71(834):249–249. doi: 10.1136/pgmj.71.834.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Colell A., García-Ruiz C., Miranda M., Ardite E., Marí M., Morales A., Corrales F., Kaplowitz N., Fernández-Checa J. C. Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Gastroenterology. 1998 Dec;115(6):1541–1551. doi: 10.1016/s0016-5085(98)70034-4. [DOI] [PubMed] [Google Scholar]
  6. Day C. P., Bashir R., James O. F., Bassendine M. F., Crabb D. W., Thomasson H. R., Li T. K., Edenberg H. J. Investigation of the role of polymorphisms at the alcohol and aldehyde dehydrogenase loci in genetic predisposition to alcohol-related end-organ damage. Hepatology. 1991 Nov;14(5):798–801. doi: 10.1002/hep.1840140509. [DOI] [PubMed] [Google Scholar]
  7. Fang C., Lindros K. O., Badger T. M., Ronis M. J., Ingelman-Sundberg M. Zonated expression of cytokines in rat liver: effect of chronic ethanol and the cytochrome P450 2E1 inhibitor, chlormethiazole. Hepatology. 1998 May;27(5):1304–1310. doi: 10.1002/hep.510270516. [DOI] [PubMed] [Google Scholar]
  8. Fataccioli V., Andraud E., Gentil M., French S. W., Rouach H. Effects of chronic ethanol administration on rat liver proteasome activities: relationship with oxidative stress. Hepatology. 1999 Jan;29(1):14–20. doi: 10.1002/hep.510290106. [DOI] [PubMed] [Google Scholar]
  9. Garbutt J. C., West S. L., Carey T. S., Lohr K. N., Crews F. T. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA. 1999 Apr 14;281(14):1318–1325. doi: 10.1001/jama.281.14.1318. [DOI] [PubMed] [Google Scholar]
  10. García-Ruiz C., Morales A., Colell A., Ballesta A., Rodés J., Kaplowitz N., Fernández-Checa J. C. Feeding S-adenosyl-L-methionine attenuates both ethanol-induced depletion of mitochondrial glutathione and mitochondrial dysfunction in periportal and perivenous rat hepatocytes. Hepatology. 1995 Jan;21(1):207–214. doi: 10.1002/hep.1840210133. [DOI] [PubMed] [Google Scholar]
  11. Grant B. F., Dufour M. C., Harford T. C. Epidemiology of alcoholic liver disease. Semin Liver Dis. 1988 Feb;8(1):12–25. doi: 10.1055/s-2008-1040525. [DOI] [PubMed] [Google Scholar]
  12. Grove J., Brown A. S., Daly A. K., Bassendine M. F., James O. F., Day C. P. The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. Pharmacogenetics. 1998 Aug;8(4):335–342. doi: 10.1097/00008571-199808000-00007. [DOI] [PubMed] [Google Scholar]
  13. Grove J., Daly A. K., Bassendine M. F., Day C. P. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology. 1997 Jul;26(1):143–146. doi: 10.1002/hep.510260119. [DOI] [PubMed] [Google Scholar]
  14. Grove J., Daly A. K., Burt A. D., Guzail M., James O. F., Bassendine M. F., Day C. P. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut. 1998 Aug;43(2):262–266. doi: 10.1136/gut.43.2.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hallé P., Paré P., Kaptein E., Kanel G., Redeker A. G., Reynolds T. B. Double-blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology. 1982 May;82(5 Pt 1):925–931. [PubMed] [Google Scholar]
  16. Imperiale T. F., McCullough A. J. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med. 1990 Aug 15;113(4):299–307. doi: 10.7326/0003-4819-113-4-299. [DOI] [PubMed] [Google Scholar]
  17. Kim S. G., Kwak J. Y., Lee J. W., Novak R. F., Park S. S., Kim N. D. Malotilate, a hepatoprotectant, suppresses CYP2E1 expression in rats. Biochem Biophys Res Commun. 1994 May 16;200(3):1414–1420. doi: 10.1006/bbrc.1994.1608. [DOI] [PubMed] [Google Scholar]
  18. Kwo P. Y., Ramchandani V. A., O'Connor S., Amann D., Carr L. G., Sandrasegaran K., Kopecky K. K., Li T. K. Gender differences in alcohol metabolism: relationship to liver volume and effect of adjusting for body mass. Gastroenterology. 1998 Dec;115(6):1552–1557. doi: 10.1016/s0016-5085(98)70035-6. [DOI] [PubMed] [Google Scholar]
  19. Lieber C. S., Robins S. J., Li J., DeCarli L. M., Mak K. M., Fasulo J. M., Leo M. A. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology. 1994 Jan;106(1):152–159. doi: 10.1016/s0016-5085(94)95023-7. [DOI] [PubMed] [Google Scholar]
  20. Luca A., García-Pagán J. C., Bosch J., Feu F., Caballería J., Groszmann R. J., Rodés J. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology. 1997 Apr;112(4):1284–1289. doi: 10.1016/s0016-5085(97)70142-2. [DOI] [PubMed] [Google Scholar]
  21. Ludwig J., Hashimoto E., Porayko M. K., Moyer T. P., Baldus W. P. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology. 1997 Mar;112(3):882–888. doi: 10.1053/gast.1997.v112.pm9041250. [DOI] [PubMed] [Google Scholar]
  22. MACDONALD R. A., JONES R. S., PECHET G. S. FOLIC ACID DEFICIENCY AND HEMOCHROMATOSIS. Arch Pathol. 1965 Aug;80:153–160. [PubMed] [Google Scholar]
  23. Maddrey W. C., Boitnott J. K., Bedine M. S., Weber F. L., Jr, Mezey E., White R. I., Jr Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978 Aug;75(2):193–199. [PubMed] [Google Scholar]
  24. Mendenhall C. L., Moritz T. E., Roselle G. A., Morgan T. R., Nemchausky B. A., Tamburro C. H., Schiff E. R., McClain C. J., Marsano L. S., Allen J. I. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology. 1993 Apr;17(4):564–576. doi: 10.1002/hep.1840170407. [DOI] [PubMed] [Google Scholar]
  25. Menon D. K., Harris M., Sargentoni J., Taylor-Robinson S. D., Cox I. J., Morgan M. Y. In vivo hepatic 31P magnetic resonance spectroscopy in chronic alcohol abusers. Gastroenterology. 1995 Mar;108(3):776–788. doi: 10.1016/0016-5085(95)90451-4. [DOI] [PubMed] [Google Scholar]
  26. Nanji A. A., Sadrzadeh S. M., Yang E. K., Fogt F., Meydani M., Dannenberg A. J. Dietary saturated fatty acids: a novel treatment for alcoholic liver disease. Gastroenterology. 1995 Aug;109(2):547–554. doi: 10.1016/0016-5085(95)90344-5. [DOI] [PubMed] [Google Scholar]
  27. Neuman M. G., Shear N. H., Bellentani S., Tiribelli C. Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells. Gastroenterology. 1998 Jul;115(1):157–166. doi: 10.1016/s0016-5085(98)70377-4. [DOI] [PubMed] [Google Scholar]
  28. Orrego H., Blake J. E., Blendis L. M., Compton K. V., Israel Y. Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med. 1987 Dec 3;317(23):1421–1427. doi: 10.1056/NEJM198712033172301. [DOI] [PubMed] [Google Scholar]
  29. Orrego H., Kalant H., Israel Y., Blake J., Medline A., Rankin J. G., Armstrong A., Kapur B. Effect of short-term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology. 1979 Jan;76(1):105–115. [PubMed] [Google Scholar]
  30. Polavarapu R., Spitz D. R., Sim J. E., Follansbee M. H., Oberley L. W., Rahemtulla A., Nanji A. A. Increased lipid peroxidation and impaired antioxidant enzyme function is associated with pathological liver injury in experimental alcoholic liver disease in rats fed diets high in corn oil and fish oil. Hepatology. 1998 May;27(5):1317–1323. doi: 10.1002/hep.510270518. [DOI] [PubMed] [Google Scholar]
  31. Ramond M. J., Poynard T., Rueff B., Mathurin P., Théodore C., Chaput J. C., Benhamou J. P. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med. 1992 Feb 20;326(8):507–512. doi: 10.1056/NEJM199202203260802. [DOI] [PubMed] [Google Scholar]
  32. Rouault T. A., Klausner R. D. Iron-sulfur clusters as biosensors of oxidants and iron. Trends Biochem Sci. 1996 May;21(5):174–177. [PubMed] [Google Scholar]
  33. Takase S., Matsuda Y., Yasuhara M., Takada A. Effects of malotilate treatment on alcoholic liver disease. Alcohol. 1989 May-Jun;6(3):219–222. doi: 10.1016/0741-8329(89)90021-9. [DOI] [PubMed] [Google Scholar]
  34. Tanaka K., Tokunaga S., Kono S., Tokudome S., Akamatsu T., Moriyama T., Zakouji H. Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol. 1998 Jun;27(3):438–443. doi: 10.1093/ije/27.3.438. [DOI] [PubMed] [Google Scholar]
  35. Tang H., Boulton R., Gunson B., Hubscher S., Neuberger J. Patterns of alcohol consumption after liver transplantation. Gut. 1998 Jul;43(1):140–145. doi: 10.1136/gut.43.1.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Taïeb J., Mathurin P., Poynard T., Gougerot-Pocidalo M. A., Chollet-Martin S. Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. Lancet. 1998 Jun 27;351(9120):1930–1931. doi: 10.1016/S0140-6736(05)78614-1. [DOI] [PubMed] [Google Scholar]
  37. Teli M. R., Day C. P., Burt A. D., Bennett M. K., James O. F. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet. 1995 Oct 14;346(8981):987–990. doi: 10.1016/s0140-6736(95)91685-7. [DOI] [PubMed] [Google Scholar]
  38. Vorobioff J., Groszmann R. J., Picabea E., Gamen M., Villavicencio R., Bordato J., Morel I., Audano M., Tanno H., Lerner E. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology. 1996 Sep;111(3):701–709. doi: 10.1053/gast.1996.v111.pm8780575. [DOI] [PubMed] [Google Scholar]
  39. Wiley T. E., McCarthy M., Breidi L., McCarthy M., Layden T. J. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998 Sep;28(3):805–809. doi: 10.1002/hep.510280330. [DOI] [PubMed] [Google Scholar]
  40. Wrenn K. D., Slovis C. M. Is intravenous thiamine safe? Am J Emerg Med. 1992 Mar;10(2):165–165. doi: 10.1016/0735-6757(92)90054-2. [DOI] [PubMed] [Google Scholar]
  41. Xu D., Thiele G. M., Beckenhauer J. L., Klassen L. W., Sorrell M. F., Tuma D. J. Detection of circulating antibodies to malondialdehyde-acetaldehyde adducts in ethanol-fed rats. Gastroenterology. 1998 Sep;115(3):686–692. doi: 10.1016/s0016-5085(98)70148-9. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES